The aim of this study was to assess the strength of hemostatic effects of ezetimibe, administered alone or in combination with simvastatin, in patients with isolated hypercholesterolemia. One hundred and four patients with isolated primary hypercholesterolemia were randomized to one of four treatment groups, simultaneously treated for 90 days with ezetimibe (10 mg daily), simvastatin (40 mg daily), ezetimibe (10 mg daily) plus simvastatin (40 mg daily), or placebo. Plasma lipids/lipoproteins and hemostatic cardiovascular risk factors were assessed on the day of randomization and after 30 and 90 days of therapy. Despite improving lipid/lipoprotein profile by both simvastatin and ezetimibe, only simvastatin reduced plasma levels/activity of fibrinogen, factor VII, factor X, von Willebrand factor, and plasminogen activator inhibitor-1. The strongest effects on plasma lipids/lipoproteins and the assessed hemostatic variables were observed when patients were treated with both simvastatin and ezetimibe. With the exception of oxidized low-density lipoproteins, the hemostatic effects of simvastatin or simvastatin plus ezetimibe did not correlate with the changes in plasma lipids/lipoproteins. Our study shows that simvastatin is a more effective agent than ezetimibe in affecting coagulation and fibrinolysis in individuals with isolated hypercholesterolemia. It also suggests that the combined administration of simvastatin and ezetimibe may bring more benefits to patients than monotherapy with only one of these agents.

References

1 Catapano A.L. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr. Med. Res. Opin. (2009) 25 431–447.
10.1185/03007990802631438
CAS PubMed Web of Science® Google Scholar
2 Davidson H. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler. Rep. (2009) 1 67–70.
10.1007/s11883-009-0011-0
Google Scholar
3 Filippatos T.D., Mikhailidis D.P. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. (2009) 15 490–516.
10.2174/138161209787315738
CAS PubMed Web of Science® Google Scholar
4 Miura S., Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern. Med. (2008) 47 1165–1170.
10.2169/internalmedicine.47.1099
PubMed Web of Science® Google Scholar
5 Yagi S., Akaike M., Aihara K. et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J. Atheroscler. Thromb. (2010) 17 173–180.
10.5551/jat.2378
CAS PubMed Web of Science® Google Scholar
6 Shaw S.M., Najam O., Khan U., Yonan N., Williams S.G., Fildes J.E. Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients in vitro. Transpl. Immunol. (2009) 211 79–82.
Google Scholar
7 Orsó E., Werner T., Wolf Z. et al. Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A (2006) 69 206–208.
10.1002/cyto.a.20229
CAS PubMed Web of Science® Google Scholar
8 Bays H.E., Neff D., Tomassini J.E. et al. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. (2008) 6 447–470.
10.1586/14779072.6.4.447
CAS PubMed Google Scholar
9 Kher N., Marsh J.D. Pathobiology of atherosclerosis – a brief review. Semin. Thromb. Hemost. (2004) 30 665–672.
10.1055/s-2004-861509
CAS PubMed Web of Science® Google Scholar
10 Saigo M., Hsue P.Y., Waters D.D. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog. Cardiovasc. Dis. (2004) 465 524–538.
10.1016/j.pcad.2004.02.003
CAS Web of Science® Google Scholar
11 Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids (2005) 40 1215–1220.
10.1007/s11745-005-1488-8
CAS PubMed Web of Science® Google Scholar
12 Krysiak R., Okopien B., Herman Z.S. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs (2003) 63 1821–1854.
10.2165/00003495-200363170-00005
CAS PubMed Web of Science® Google Scholar
13 Turfaner N., Uzun H., Balci H. et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South. Med. J. (2010) 103 428–433.
10.1097/SMJ.0b013e3181d83374
PubMed Web of Science® Google Scholar
14 Pitsavos C., Skoumas I., Tousoulis D. et al. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int. J. Cardiol. (2009) 134 280–281.
10.1016/j.ijcard.2007.12.065
PubMed Web of Science® Google Scholar
15 Kostakou P., Kolovou G., Anagnostopoulou K. et al. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand’s factor and C-reactive protein in patients with hypercholesterolaemia. Arch. Cardiovasc. Dis. (2010) 103 26–32.
10.1016/j.acvd.2009.10.003
PubMed Web of Science® Google Scholar
16 Yamamoto K., Shibayama S., Takeshita K., Kojima T., Takamatsu J. A novel cholesterol absorption inhibitor, ezetimibe, decreases adipose-derived and vascular PAI-1 expression in vivo. Thromb. Res. (2009) 124 644–645.
10.1016/j.thromres.2009.05.011
CAS PubMed Web of Science® Google Scholar
17 Piorkowski M., Fischer S., Stellbaum C. et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J. Am. Coll. Cardiol. (2007) 49 1035–1042.
10.1016/j.jacc.2006.10.064
CAS PubMed Web of Science® Google Scholar
18 Malmström R.E., Settergren M., Böhm F., Pernow J., Hjemdahl P. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb. Haemost. (2009) 101 157–164.
PubMed Web of Science® Google Scholar
19 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7–22.
10.1016/S0140-6736(02)09327-3
PubMed Web of Science® Google Scholar
20 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group. Lancet (1994) 344 1383–1389.
PubMed Web of Science® Google Scholar
21 Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333 1301–1307.
10.1056/NEJM199511163332001
CAS PubMed Web of Science® Google Scholar
22 Krysiak R., Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J. Cardiovasc. Pharmacol. (2011) Feb 3. [Epub ahead of print].
10.1097/FJC.0b013e318211703b
PubMed Web of Science® Google Scholar
23 Kastelein J.J., Akdim F., Stroes E.S. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. (2008) 358 1431–1443.
10.1056/NEJMoa0800742
CAS PubMed Web of Science® Google Scholar
24 Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. (2008) 359 1343–1356.
10.1056/NEJMoa0804602
PubMed Web of Science® Google Scholar
25 Kita T., Kume N., Minami M. et al. Role of oxidized LDL in atherosclerosis. Ann. N Y Acad. Sci. (2001) 947 199–205.
10.1111/j.1749-6632.2001.tb03941.x
CAS PubMed Web of Science® Google Scholar
26 Jasinska M., Owczarek J., Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. (2007) 59 483–499.
CAS PubMed Web of Science® Google Scholar
27 Dahlback B. Blood coagulation. Lancet (2000) 355 1627–1632.
10.1016/S0140-6736(00)02225-X
CAS PubMed Web of Science® Google Scholar
28 Seedorf U., Engel T., Lueken A. et al. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem. Biophys. Res. Commun. (2004) 320 1337–1341.
10.1016/j.bbrc.2004.06.092
CAS PubMed Web of Science® Google Scholar
29 Wilson H.M., Barker R.N., Erwig L.P. Macrophages: promising targets for the treatment of atherosclerosis. Curr. Vasc. Pharmacol. (2009) 7 234–243.
10.2174/157016109787455635
CAS PubMed Web of Science® Google Scholar
30 Hickmott H., Wynne H., Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb. Haemost. (2003) 89 949–950.
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume26, Issue3

June 2012

Pages 424-431

The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia

Abstract

References

Citing Literature

References

Related

Information